S-Space College of Medicine/School of Medicine (의과대학/대학원) Program in Clinical Pharmacology (협동과정-임상약리학전공) Journal Papers (저널논문_협동과정-임상약리학전공)
Pemetrexed and cisplatin in patients with advanced gastric cancer: a Korean cancer study group multicenter phase II study
- Kim, Yeul Hong; Chung, Hyun Cheol; Kang, Won Ki; Park, Sook Ryun; Kim, Chul Soo; Kim, Tae-Yue; Shin, Sang Won; Park, Byung-Joo; Cha, Soo Jin; Bang, Yung-Jue
- Issue Date
- Springer Verlag
- Cancer Chemother Pharmacol 62:263-270
- Adenocarcinoma/*drug therapy/mortality/pathology; Antineoplastic Combined Chemotherapy Protocols/administration &; dosage/adverse effects/*therapeutic use; Cisplatin/administration & dosage/adverse effects/therapeutic use; Disease-Free Survival; Glutamates/administration & dosage/adverse effects/therapeutic use; Guanine/administration & dosage/adverse effects/analogs &; derivatives/therapeutic use; Infusions, Intravenous; Korea; Neoplasm Invasiveness; Stomach Neoplasms/*drug therapy/mortality/pathology
- BACKGROUND: Pemetrexed is a multitargeted antifolate enzyme inhibitor, which has activity against a variety of tumors, including advanced gastric cancer (AGC). The aim of this study was to assess efficacy and safety of pemetrexed plus cisplatin (PemCis) combination in the treatment of AGC in Korean patients. PATIENTS AND METHODS: This was a multicenter, single arm, open label study. Patients with no prior palliative chemotherapy received pemetrexed 500 mg/m(2) and cisplatin 75 mg/m(2) day 1, every 3 weeks plus folic acid and vitamin B(12) supplementation. Response rate was assessed according to response evaluation criteria in solid tumors (RECIST) criteria. RESULTS: Of the 50 patients evaluable for efficacy, 13 had partial response for an overall response rate of 26% (95% CI, 14.6-40.3%) and 15 (30%) had stable disease. Median time to progression was 2.8 months (95%CI, 2.2-4.4 months), and median overall survival was 6.6 months (95% CI, 4.8-10.4 months). Of the 51 patients evaluable for safety, the most frequent NCI-CTC grade 3/4 toxicities were neutropenia in 49% of patients (25% of cycles) and anorexia in 10% of patients (4% of cycles). CONCLUSION: PemCis has a modest activity and acceptable toxicity profile in patients with AGC. Clinical trials with different combinations and dose regimens are, therefore, warranted.
- 0344-5704 (Print)
- Files in This Item: There are no files associated with this item.